DK1056477T3 - Naopartikler omfattende polyisobutylcyanoacrylat og cyclodextriner - Google Patents

Naopartikler omfattende polyisobutylcyanoacrylat og cyclodextriner

Info

Publication number
DK1056477T3
DK1056477T3 DK99906300T DK99906300T DK1056477T3 DK 1056477 T3 DK1056477 T3 DK 1056477T3 DK 99906300 T DK99906300 T DK 99906300T DK 99906300 T DK99906300 T DK 99906300T DK 1056477 T3 DK1056477 T3 DK 1056477T3
Authority
DK
Denmark
Prior art keywords
naoparticles
polyisobutylcyanoacrylate
cyclodextrins
active ingredient
nanoparticles
Prior art date
Application number
DK99906300T
Other languages
Danish (da)
English (en)
Inventor
Da Silveira Airton Monza
Gilles Ponchel
Dominique Duchene
Patrick Couvreur
Francis Puisieux
Original Assignee
Bioalliance Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioalliance Pharma Sa filed Critical Bioalliance Pharma Sa
Application granted granted Critical
Publication of DK1056477T3 publication Critical patent/DK1056477T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK99906300T 1998-02-27 1999-02-24 Naopartikler omfattende polyisobutylcyanoacrylat og cyclodextriner DK1056477T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9802429A FR2775435B1 (fr) 1998-02-27 1998-02-27 Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs

Publications (1)

Publication Number Publication Date
DK1056477T3 true DK1056477T3 (da) 2006-04-18

Family

ID=9523473

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99906300T DK1056477T3 (da) 1998-02-27 1999-02-24 Naopartikler omfattende polyisobutylcyanoacrylat og cyclodextriner

Country Status (12)

Country Link
US (1) US6881421B1 (xx)
EP (1) EP1056477B1 (xx)
JP (1) JP4651192B2 (xx)
AT (1) ATE311906T1 (xx)
AU (1) AU753573B2 (xx)
CA (1) CA2320928C (xx)
DE (1) DE69928776T2 (xx)
DK (1) DK1056477T3 (xx)
ES (1) ES2255246T3 (xx)
FR (1) FR2775435B1 (xx)
IL (2) IL137882A0 (xx)
WO (1) WO1999043359A1 (xx)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001251136A1 (en) 2000-04-06 2001-10-23 University Technology Corporation Compositions and methods for promoting wound healing
FR2808691B1 (fr) * 2000-05-12 2005-06-24 Coletica Cyclodextrines substituees preferentiellement sur leur face primaire par des fonctions acide ou amine
FR2816949B1 (fr) * 2000-11-17 2003-11-28 Centre Nat Rech Scient Copolymere a structure sequencee compose d'un segment saccharidique lie a au moins un segment hydrophobe bioerodable, et particules correspondantes
US6890703B2 (en) 2002-03-06 2005-05-10 International Business Machines Corporation Preparation of crosslinked particles from polymers having activatible crosslinking groups
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
JP4865990B2 (ja) * 2002-04-12 2012-02-01 エラン ファーマ インターナショナル，リミティド ナノ粒子メゲストロール製剤
FR2841137B1 (fr) * 2002-06-20 2004-08-13 Bioalliance Pharma Systeme de vectorisation comprenant des nanoparticules de taille homogene d'au moins un polymere et d'au moins un polysaccharide charge positivement
CN100518831C (zh) * 2002-08-15 2009-07-29 刘云清 固体纳米药物及其制备方法
US20050051968A1 (en) * 2002-11-13 2005-03-10 Froesel David William Washer toss game
US8128954B2 (en) 2004-06-07 2012-03-06 California Institute Of Technology Biodegradable drug-polymer delivery system
FR2872703B1 (fr) * 2004-07-07 2006-10-06 Ethypharm Sa Nanoparticules polymeriques composites
EP1796650B1 (en) * 2004-09-14 2009-01-07 NanoDel Technologies GmbH Delivery vehicle containing nanoparticles
CA2580529A1 (en) * 2004-10-01 2006-04-13 Eisai R & D Management Co., Ltd. Fine particle-containing composition and manufacturing method therefor
WO2007047253A2 (en) * 2005-10-11 2007-04-26 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
KR100726720B1 (ko) 2005-12-26 2007-06-11 코스맥스 주식회사 수난용성 활성물질을 하이드록시알킬화 사이클로덱스트린과리포좀으로 이중 안정화 시킨 나노캡슐 리포좀 조성물
KR20090045205A (ko) * 2006-06-26 2009-05-07 뮤추얼 파마슈티컬 컴퍼니 아이엔씨. 활성제 제형 및 이의 제조방법 및 사용방법
US8679539B2 (en) * 2007-01-31 2014-03-25 Tong Shen Enterprise Co., Ltd. Drug-loaded poly (alkyl-cyanoacrylate) nanoparticles and process for the preparation thereof
JP5224313B2 (ja) * 2007-02-27 2013-07-03 公立大学法人横浜市立大学 プラスミド送達用粒子
ES2310122B1 (es) * 2007-04-20 2009-10-30 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
US9132296B2 (en) 2007-05-17 2015-09-15 Ag Essence Antimicrobial solution and methods of making and using the same
US8729121B2 (en) 2007-06-25 2014-05-20 Adhezion Biomedical, Llc Curing accelerator and method of making
WO2009064291A1 (en) 2007-11-14 2009-05-22 Spartan Medical Products, Llc Cyanoacrylate tissue adhesives
WO2009084494A1 (ja) 2007-12-27 2009-07-09 Public University Corporation Yokohama City University グラム陽性細菌用抗菌剤
US8293838B2 (en) * 2008-06-20 2012-10-23 Adhezion Biomedical, Llc Stable and sterile tissue adhesive composition with a controlled high viscosity
US8198344B2 (en) 2008-06-20 2012-06-12 Adhezion Biomedical, Llc Method of preparing adhesive compositions for medical use: single additive as both the thickening agent and the accelerator
US20110117047A1 (en) 2008-06-23 2011-05-19 Adhezion Biomedical, Llc Cyanoacrylate tissue adhesives with desirable permeability and tensile strength
EP2153821A1 (en) * 2008-08-06 2010-02-17 BioAlliance Pharma Oral formulations of camptothecin derivatives
US8652510B2 (en) 2008-10-31 2014-02-18 Adhezion Biomedical, Llc Sterilized liquid compositions of cyanoacrylate monomer mixtures
US9254133B2 (en) 2008-10-31 2016-02-09 Adhezion Biomedical, Llc Sterilized liquid compositions of cyanoacrylate monomer mixtures
US8609128B2 (en) * 2008-10-31 2013-12-17 Adhezion Biomedical, Llc Cyanoacrylate-based liquid microbial sealant drape
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
US8629151B2 (en) 2009-05-27 2014-01-14 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
US20100311838A1 (en) 2009-05-29 2010-12-09 Pipkin James D Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
US9309019B2 (en) 2010-05-21 2016-04-12 Adhezion Biomedical, Llc Low dose gamma sterilization of liquid adhesives
EP2575773A4 (en) 2010-05-26 2014-06-25 Selecta Biosciences Inc SYNTHETIC NANOTRÄGERKOMBINATIONSIMPFSTOFFE
FR2968662B1 (fr) 2010-12-10 2013-11-22 Roussy Inst Gustave Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
AU2012233439A1 (en) 2011-03-31 2013-11-14 Nanocame Co., Ltd. Novel preparation technique for higher-order structure that exhibits anti-cellular effect
PL2508207T3 (pl) * 2011-03-31 2013-09-30 Bioalliance Pharma Nanocząsteczki zawierające chemioterapeutyczny lek przeciwnowotworowy
WO2012149393A2 (en) 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells
CN103702687A (zh) 2011-07-29 2014-04-02 西莱克塔生物科技公司 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
SG11201400744XA (en) 2011-09-23 2014-04-28 Emerald Hilton Davis Llc Self-assembled nano-structure particle and method for preparing
US10988618B2 (en) 2011-09-23 2021-04-27 Dystar Hilton Davis Corp. Self-assembled nano-structured particle and methods for preparing
JP6192543B2 (ja) * 2012-01-19 2017-09-06 昇一 城武 植物病原細菌用抗菌剤
CN102579402B (zh) * 2012-03-26 2013-07-03 山东大学 一种负载紫杉醇的囊泡的制备方法
US11547116B2 (en) 2012-12-12 2023-01-10 William Wingfield Metal oxide compounds and infusion into polymer compounds
JP6533213B2 (ja) * 2014-02-27 2019-06-19 昇一 城武 抗ウイルス剤
US9421297B2 (en) 2014-04-02 2016-08-23 Adhezion Biomedical, Llc Sterilized compositions of cyanoacrylate monomers and naphthoquinone 2,3-oxides
WO2017046037A1 (en) 2015-09-14 2017-03-23 Onxeo Nanoparticles loaded with active ingredients, their process of preparation and their uses
US20200121699A1 (en) 2016-02-22 2020-04-23 Onxeo Combination therapies comprising immuno-oncology agents and belinostat
US11491114B2 (en) 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
AU2018256435A1 (en) 2017-04-20 2019-11-07 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
PE20210685A1 (es) 2018-07-03 2021-04-08 Gilead Sciences Inc Anticuerpos que se dirigen al gp120 de vih y metodos de uso
CA3142513A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
KR20220047277A (ko) 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
CN117843811A (zh) 2019-09-30 2024-04-09 吉利德科学公司 Hbv疫苗和治疗hbv的方法
CA3128035A1 (en) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Combination therapies for delivery across the blood brain barrier
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504408B1 (fr) * 1981-04-24 1986-02-14 Couvreur Patrick Procede de preparation de particules submicroscopiques, particules ainsi obtenues et compositions pharmaceutiques les contenant
US5246611A (en) * 1990-05-09 1993-09-21 The Procter & Gamble Company Non-destructive carriers for cyclodextrin complexes
AU8514291A (en) * 1990-09-14 1992-04-15 St. George's Enterprises Limited Particulate agents
FR2692168B1 (fr) * 1992-06-16 1995-03-24 Centre Nat Rech Scient Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères.
DE69432867T2 (de) * 1993-11-18 2004-04-22 Sirtex Medical Ltd., Burswood Zubereitung mit gesteuerter freisetzung
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin

Also Published As

Publication number Publication date
FR2775435B1 (fr) 2000-05-26
AU2628799A (en) 1999-09-15
IL137882A (en) 2006-12-31
EP1056477A1 (fr) 2000-12-06
JP2002504526A (ja) 2002-02-12
JP4651192B2 (ja) 2011-03-16
DE69928776T2 (de) 2006-09-07
EP1056477B1 (fr) 2005-12-07
US6881421B1 (en) 2005-04-19
ES2255246T3 (es) 2006-06-16
WO1999043359A1 (fr) 1999-09-02
CA2320928A1 (fr) 1999-09-02
FR2775435A1 (fr) 1999-09-03
DE69928776D1 (de) 2006-01-12
CA2320928C (fr) 2009-12-15
IL137882A0 (en) 2001-10-31
AU753573B2 (en) 2002-10-24
ATE311906T1 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
DK1056477T3 (da) Naopartikler omfattende polyisobutylcyanoacrylat og cyclodextriner
DK1200418T3 (da) Nematodicide trifluorbutener
DE60019693D1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
CY1105399T1 (el) Μεθοδος επιλεκτικης υποκαταστασεως των ταξανων
MXPA03011006A (es) Compuestos de cicloalquil urea benzo-fusionados 1,4-disustituidos.
FR2451192A1 (fr) Agent de prevention de la mauvaise haleine contenant de la cyclodextrine
AP9901478A0 (en) Compounds for the treatment of ischemia.
BR0008176A (pt) Derivados anti-convulsivantes úteis no tratamento de cefaléias em cacho
HK1028548A1 (en) Formulations for hydrophobic pharmaceutical agents
AU2001272516A1 (en) Anti-slip protection device for a housing head for medical instruments
ZA979961B (en) 5-HT1F agonists
NZ527157A (en) Compositions for delivering bisphosphonates
DK1009385T3 (da) Kolesterolsænkende komposition
YU72594A (sh) Vodeni rastvor inkluzionih kompleksa benzotiofen jedinjenja sa vodorastvornim ciklodekstrinima, njegove farmaceutske formulacije i postupci za dobijanje
MXPA03001536A (es) (aminoalcoxibenzoil) benzofuranos o benzotiofenos, metodo para preparar los mismo y composiciones que los contienen.
ATE363920T1 (de) Hydrophobe iodverbindung enthaltende liposome
EP1073447A4 (en) N1-MODIFIED GLYCOPEPTIDES
ID28892A (id) Sintesa heteropoliasida
IL135634A0 (en) 5-htif agonists
AU3315200A (en) 1,5-anhydro-d-fructose substituted with a hydrophobic group for use as anti-oxidant and/or emulsifier
DE60006063D1 (de) Bis-terpyridinplatinkomplexe
WO2005054303A3 (fr) Dimères de cyclodextrines et leurs dérivés, leurs procédés de préparation et leur utilisation notamment pour la solubilisation de substances pharmacologiquement actives
BG107553A (en) Aminoalkenylbenzoyl-benzofuran or benzothiophene derivatives, methods for preparing same and compositions containing same
DE69807200D1 (de) Inklusionskomplexe in waessriger loesung
HUP0101455A2 (hu) Stabil antibakteriális, aromás karbanilidszármazékot tartalmazó készítmény, és eljárás karbanilidszármazék stabilizálására